- Home
- AUST vs NNVC Comparison
AUST vs NNVC Comparison
Compare AUST & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | NNVC |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 21.2M |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AUST | NNVC |
|---|---|---|
| Price | $1.36 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.6K | ★ 220.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $0.85 |
| 52 Week High | $3.92 | $2.23 |
Technical Indicators
Market Signals| Indicator | AUST | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 55.02 |
| Support Level | $1.24 | $1.09 |
| Resistance Level | $1.59 | $1.29 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 13.24 | 44.81 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.